Ophthotech Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference

Webcast Available Through Ophthotech Website

NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (NASDAQ: OPHT) announced today that David R.
Guyer, M.D., Chief Executive Officer and Chairman of the Board, will
present an overview of the Company at the 34th Annual J.P. Morgan
Healthcare Conference in San Francisco on Monday, January 11, 2016 at
2:30 p.m. Pacific Time (5:30 p.m. Eastern Time).

Investors and the general public are invited to listen to a live webcast
of the presentation at www.ophthotech.com.
Please connect to Ophthotech’s website several minutes prior to the
start of the presentation to ensure adequate time for any software
download that may be necessary. A replay will be available for 14 days
following the presentation.

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the
development of novel therapeutics to treat back of the eye diseases,
with a focus on developing innovative therapies for age-related macular
degeneration (AMD). Ophthotech’s most advanced product candidate, Fovista®
anti-PDGF therapy, is in Phase 3 clinical trials for use in combination
with anti-VEGF therapy that represents the current standard of care for
the treatment of wet AMD. Ophthotech’s second product candidate, Zimura®,
an inhibitor of complement factor C5, is being developed for the
treatment of geographic atrophy, a form of dry AMD. For more
information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech’s future
expectations, plans and prospects constitute forward-looking statements
for purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Any forward-looking statements represent
Ophthotech’s views only as of the date of this press release. Ophthotech
anticipates that subsequent events and developments will cause its views
to change. While Ophthotech may elect to update these forward-looking
statements at some point in the future, Ophthotech specifically
disclaims any obligation to do so.



Ophthotech Corporation
Kathy Galante,
Vice President, Investor Relations and Corporate
LLC on behalf of Ophthotech Corporation
Jennifer Devine,
973-442-1555 ext. 102